Halozyme Therapeutics, Inc.

Description:

Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program, investigational drug PEGPH20 (pegvorhyaluronidase alfa), applies a unique approach to targeting solid tumors, potentially providing increased immune response and tumor access for co-administered anti-cancer therapies.

In addition to our proprietary product pipeline, Halozyme has value-driving partnerships with leading pharmaceutical companies, including Roche, Pfizer, Janssen, Baxalta, AbbVie, Eli Lilly, Bristol-Myers Squibb and Alexion for our ENHANZE® drug delivery technology, which enables biologics and small molecules currently administered intravenously to be delivered subcutaneously and may provide additional benefits. We are headquartered in San Diego.

Mission:

We transform and enhance lives through the discovery, development and commercialization of biopharmaceuticals.